Rabies virus (RABV) is able to reach the central nervous system (CNS) without triggering a strong immune response, using multiple mechanisms to evade and suppress the host immune system. After infection a bite or scratch from a rabid animal, RABV comes into contact with macrophages, which are the first antigen-presenting cells (APCs) that are recruited to the area and play an essential role in the onset of a specific immune response. It is poorly understood how RABV affects macrophages, and if the interaction contributes to the observed immune suppression. This study was undertaken to characterize the interactions between RABV and human monocyte-derived macrophages (MDMs). We showed that street RABV does not replicate in human MDMs. Using a recombinant trimeric RABV glycoprotein (rRABV-tG) we showed binding to the nicotinic acetylcholine receptor alpha 7 (nAChr α7) on MDMs, and confirmed the specificity using the nAChr α7 antagonist alpha-bungarotoxin (α-BTX). We found that this binding induced the cholinergic anti-inflammatory pathway (CAP), characterized by a significant decrease in tumor necrosis factor α (TNF-α) upon LPS challenge. Using confocal microscopy we found that induction of the CAP is associated with significant cytoplasmic retention of nuclear factor κB (NF-κB). Co-cultures of human MDMs exposed to street RABV and autologous T cells further revealed that the observed suppression of MDMs might affect their function as T cell activators as well, as we found a significant decrease in proliferation of CD8 T cells and an increased production of the anti-inflammatory cytokine IL-10. Lastly, using flow cytometric analysis we observed a significant increase in expression of the M2-c surface marker CD163, hinting that street RABV might be able to affect macrophage polarization. Taken together, these results show that street RABV is capable of inducing an anti-inflammatory state in human macrophages, possibly affecting T cell functioning.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933221PMC
http://dx.doi.org/10.3389/fimmu.2021.622516DOI Listing

Publication Analysis

Top Keywords

street rabv
20
nachr α7
12
rabv
9
cholinergic anti-inflammatory
8
anti-inflammatory pathway
8
human monocyte-derived
8
monocyte-derived macrophages
8
immune response
8
human mdms
8
street
5

Similar Publications

The Immune Escape Strategy of Rabies Virus and Its Pathogenicity Mechanisms.

Viruses

November 2024

State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Guangxi University, Nanning 530004, China.

In contrast to most other rhabdoviruses, which spread by insect vectors, the rabies virus (RABV) is a very unusual member of the Rhabdoviridae family, since it has evolved to be fully adapted to warm-blooded hosts and spread directly between them. There are differences in the immune responses to laboratory-attenuated RABV and wild-type rabies virus infections. Various investigations showed that whilst laboratory-attenuated RABV elicits an innate immune response, wild-type RABV evades detection.

View Article and Find Full Text PDF
Article Synopsis
  • - Rabies virus (RABV) is a deadly virus that causes rabies, categorized into fixed laboratory strains and street strains found in the wild, each with different traits.
  • - The Toyohashi strain is a street strain from Japan that was derived from a rabid dog bite and has been used to create a reverse genetics system for research.
  • - Researchers developed a recombinant Toyohashi strain that allows tracking of viral proteins in living cells, making it a valuable resource for studying how rabies street strains replicate at the molecular level.
View Article and Find Full Text PDF

β-d-N-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus.

Antiviral Res

September 2024

Laboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., Osaka, Japan; Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan. Electronic address:

Rabies is a fatal neurological disorder caused by rabies virus (RABV) infection. Approximately 60,000 patients die from rabies annually, and there are no effective treatments for this disease. Nucleoside analogs are employed as antiviral drugs based on their broad antiviral spectrum, and certain nucleoside analogs have been reported to exhibit anti-RABV activity.

View Article and Find Full Text PDF
Article Synopsis
  • Rabies in the European Union is almost eliminated due to vaccination campaigns aimed at wildlife, especially red foxes.
  • These campaigns involve giving out bait laced with a vaccine, and scientists check how well the vaccination is working by collecting samples from foxes and analyzing them.
  • A study suggests that the way the vaccine is tested needs to be the same across the EU to better understand its effectiveness, and it also found that hotter weather might make the vaccination campaigns less effective.
View Article and Find Full Text PDF

Development of a novel bispecific antibody GR1801 for rabies.

J Med Virol

August 2023

Division of Monoclonal Antibody Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, China.

Rabies is a zoonotic viral disease characterized by an almost 100% fatality rate once symptoms appear. However, it can be prevented through timely postexposure prophylaxis (PEP). Currently, there is a growing trend to replace polyclonal rabies immune globulin (RIG) with monoclonal antibodies (mAbs) in rabies PEP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!